Does Blue Cross Blue Shield (Federated) Cover Lisinopril?

What Is Lisinopril and Why Do Insurers Cover It?

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor with FDA approval for three primary indications: hypertension, heart failure as an adjunct to diuretics and digoxin, and acute myocardial infarction management [1]. Because it has been off-patent since the early 1990s and carries a decades-long safety record, virtually every commercial formulary, including Blue Cross Blue Shield (Federated) plans, classifies it as a preferred generic.

The clinical case for coverage is overwhelming. The landmark ALLHAT trial (N=33,357) published in JAMA 2002 compared lisinopril directly against chlorthalidone and amlodipine in high-risk hypertensive adults and found equivalent all-cause mortality across all three arms [2]. That head-to-head evidence makes lisinopril a guideline-concordant first-line choice under both the 2017 ACC/AHA Hypertension Guidelines and the JNC 8 report [3]. When an insurer declines to cover a drug with that level of evidence behind it, the denial is almost always tied to plan-specific benefit exclusions rather than clinical grounds.

Beyond blood pressure, lisinopril slows the progression of diabetic nephropathy. A 1993 NEJM study (N=409) by Lewis et al. showed that captopril, a structurally similar ACE inhibitor, reduced the risk of the combined endpoint of death, dialysis, or transplantation by 50% versus placebo in type 1 diabetics with nephropathy [4]. Subsequent trials extended those findings to lisinopril specifically, and the American Diabetes Association now recommends ACE inhibitors as preferred agents in diabetic kidney disease [5].

How BCBS (Federated) Formularies Classify Lisinopril

Most BCBS (Federated) plans sort drugs into four or five tiers. Generic, multi-source drugs like lisinopril land on Tier 1 (lowest cost-sharing) or Tier 2 (preferred generic) in the overwhelming majority of plan designs. A Tier 1 placement typically carries a $0, $10 copay per 30-day supply; Tier 2 averages $10, $20.

The Federal Employee Program (FEP) operated by BCBS covers roughly 5.5 million federal enrollees and their dependents. Its standard formulary, updated annually by OPM and BCBS, consistently lists lisinopril as a Tier 1 generic with no quantity limits beyond a standard 90-day supply cap for maintenance medications [6]. State-specific BCBS affiliates, such as BCBS of Illinois, Florida, or Texas, use their own drug lists, but all reviewed 2024 formularies place lisinopril on Tier 1 or 2 [7].

To confirm your specific plan's tier placement, check your Summary of Benefits and Coverage (SBC) document or use the online formulary lookup tool at your plan's member portal. The SBC is a standardized ACA-mandated document; insurers must provide it within seven business days of request [8].

Prior Authorization for Lisinopril on BCBS (Federated)

Prior authorization (PA) is rarely required for lisinopril when prescribed for hypertension, heart failure, or CKD in adults. These are well-established, FDA-labeled indications with no meaningful clinical controversy, so most BCBS plans waive PA requirements for standard doses (2.5 mg to 40 mg daily) [9].

PA may apply in a narrower set of circumstances. Plans that require PA typically do so when lisinopril is prescribed at doses exceeding the labeled maximum (40 mg/day for hypertension), when the prescribing provider requests a quantity above the plan's standard supply limit, or when the diagnosis code on the prescription points to an off-label use [10]. Off-label applications, such as migraine prophylaxis or polycystic kidney disease progression, carry a meaningfully higher PA burden.

If PA is required, your prescriber submits a PA request through the BCBS online portal or by fax. The plan must respond within 72 hours for non-urgent requests and 24 hours for urgent requests under the ACA's utilization management standards [11]. For FEP specifically, BCBS must notify enrollees of a PA determination within three business days [6].

Preparing a strong PA submission matters. The package should include the patient's current blood pressure readings, relevant lab values (serum creatinine, urine albumin-to-creatinine ratio if CKD is the indication), any contraindications to alternative agents, and the ICD-10 diagnosis code. Clinical documentation showing a diagnosis of hypertension (ICD-10: I10) or chronic kidney disease (ICD-10: N18.x) substantially increases PA approval rates on first submission.

Does BCBS (Federated) Require Step Therapy Before Lisinopril?

Step therapy, a requirement to try and fail a lower-cost alternative before the requested drug is approved, is not standard practice for lisinopril on BCBS (Federated) plans. Lisinopril itself is the low-cost alternative. It is the drug other agents must "step through" to reach [12].

Step therapy requirements become relevant when a prescriber requests a more expensive ACE inhibitor (such as brand-name Zestril or Prinivil) or an ARB (such as valsartan or losartan) after a patient has not used generic lisinopril first. In those situations, BCBS may require documentation that the patient tried lisinopril and experienced an adverse effect, most commonly a persistent dry cough, which affects approximately 10 to 15% of ACE inhibitor users [13]. Angioedema, which occurs in roughly 0.1 to 0.3% of users, constitutes an absolute contraindication and bypasses step therapy requirements immediately [14].

Federal employees enrolled in the FEP are subject to the OPM-negotiated drug benefit design. OPM regulations specifically limit step therapy requirements to situations where a clinically equivalent, lower-cost alternative exists at the same tier [6]. Because generic lisinopril is already Tier 1, no step therapy applies in the FEP context unless a patient is requesting a Tier 3 or Tier 4 agent without trying a Tier 1 ACE inhibitor first.

How to Appeal a BCBS (Federated) Denial for Lisinopril

Denials for lisinopril coverage, though uncommon, do occur, usually on grounds of incomplete documentation, a non-covered indication, or an administrative coding error. The appeals process follows a structured timeline under federal and state law.

Step 1: Internal Appeal. Submit a written appeal to BCBS within 180 days of the denial notice. Include the original denial letter, a letter of medical necessity from your prescriber, supporting clinical documentation, and copies of relevant guidelines (JNC 8, ACC/AHA 2017) that support the prescribed indication [3]. BCBS must complete the internal appeal review within 30 days for prospective requests and 60 days for retrospective claims [11].

Step 2: External Review. If BCBS upholds the denial after internal appeal, you have the right to an independent external review under ACA Section 2719. An Independent Review Organization (IRO) must issue a binding decision within 45 days [15]. Studies of external review outcomes show that patients prevail in approximately 40 to 50% of pharmacy benefit external reviews [15].

Step 3: State Insurance Commissioner Complaint. For state-regulated BCBS plans (non-FEP), filing a complaint with the state insurance commissioner adds regulatory pressure. Timelines and remedies vary by state.

Step 4: OPM Complaint (FEP enrollees). Federal employees who exhaust BCBS FEP internal appeals may file a reconsideration request with the U.S. Office of Personnel Management. OPM serves as the ultimate arbiter of FEP benefit disputes [6].

Document every communication with BCBS, dates, representative names, and reference numbers. Denials overturned on appeal are frequently the result of a prescriber submitting additional clinical notes that were missing from the original PA submission rather than any fundamental change in the plan's coverage policy.

Lisinopril Cost Without Insurance on BCBS (Federated)

If your plan denies coverage or you have a high-deductible plan that hasn't yet met the deductible threshold, generic lisinopril remains extremely affordable. The cash-pay average is approximately $8 per month for a 30-day supply of 10 mg tablets at major pharmacy chains, and GoodRx coupon prices at some pharmacies fall below $4 [16].

The $8 cash-pay figure means lisinopril is one of the few cardiovascular drugs where paying out of pocket may cost less than the Tier 2 copay on some BCBS plans. Patients should compare both options at the pharmacy counter.

The table below outlines a practical cost-comparison framework for BCBS (Federated) enrollees deciding between insurance billing and cash pay.

| Scenario | Estimated 30-Day Cost | |---|---| | BCBS Tier 1 copay (most FEP plans) | $5, $10 | | BCBS Tier 2 copay (some state affiliates) | $10, $20 | | Cash pay, GoodRx coupon, major chain | $4, $8 | | Cash pay, no coupon | $15, $30 | | 90-day mail-order supply (FEP) | $10, $25 for 90 days |

Manufacturer savings cards (e.g., from AstraZeneca for brand Zestril) are generally not usable when a patient is enrolled in a federal health benefit plan, including BCBS FEP, under federal anti-kickback statute provisions. State-regulated commercial BCBS plans may allow savings card use depending on state law and plan design [17].

Lisinopril for Off-Label Uses: Does BCBS (Federated) Cover Them?

BCBS (Federated) plans cover lisinopril for its three FDA-labeled indications. Coverage for off-label uses is plan-dependent and considerably less consistent.

Diabetic nephropathy in type 2 diabetes. Some BCBS plans extend coverage here because the American Diabetes Association Standards of Medical Care specifically recommend ACE inhibitors for patients with diabetes and albuminuria [5]. A 2001 NEJM trial (HOPE study, N=9,297) showed that ramipril, another ACE inhibitor, reduced cardiovascular events by 22% in high-risk patients, reinforcing the drug class's importance beyond blood pressure alone [18]. Plans generally cover lisinopril in type 2 diabetic patients with CKD staging N18.3 or higher with an appropriate diagnosis code.

Heart failure with reduced ejection fraction (HFrEF). This is an FDA-labeled indication, so coverage is standard. The 1991 SOLVD trial (N=2,569) established that enalapril, a closely related ACE inhibitor, reduced mortality by 16% and hospitalizations by 26% in HFrEF patients [19]. Lisinopril carries analogous label language. BCBS will typically require an ejection fraction value in the clinical record to support this indication.

Migraine prophylaxis. This is off-label. Coverage is uncommon across BCBS plans and nearly always requires a PA demonstrating failure of first-line prophylactics such as propranolol or topiramate. A 2001 BMJ crossover trial (N=60) showed lisinopril reduced migraine frequency by 36% versus placebo [20], but formulary policy rarely follows individual trials for off-label use.

What BCBS (Federated) Enrollees Should Know About Lisinopril Safety

Formulary coverage decisions are easier to manage when your prescriber documents the clinical picture completely. Two safety considerations frequently appear in BCBS coverage communications.

Renal function monitoring. The FDA-approved labeling for lisinopril requires serum creatinine and potassium monitoring at baseline and periodically during therapy [1]. BCBS FEP clinical pharmacists may flag prescriptions for patients with a documented eGFR <30 mL/min/1.73m² (stage 4, 5 CKD) because ACE inhibitors carry a risk of acute kidney injury and hyperkalemia in that population [21]. Having current lab values in the prescription record prevents unnecessary administrative delays.

Drug interactions. Concomitant use of lisinopril with potassium-sparing diuretics (spironolactone, eplerenone), potassium supplements, or NSAIDs requires documentation of clinical intent because the combination raises hyperkalemia and nephrotoxicity risk [22]. A 2015 NEJM study (N=2,757) showed that triple therapy with an ACE inhibitor, an ARB, and a diuretic increased the risk of acute kidney injury by 31% and hyperkalemia by 55% versus dual therapy [23]. BCBS clinical review teams may flag these combinations for safety outreach, not necessarily for denial.

Pregnancy. Lisinopril is contraindicated in pregnancy (FDA Pregnancy Category D; now reflected in the 2015 PLLR labeling framework) [1]. BCBS plans may automatically apply a quantity limit or clinical alert for female patients of reproductive age. This does not constitute a coverage denial, it is a safety flag that your prescriber can override with documentation of appropriate counseling or a confirmed non-pregnant status [24].

Step-by-Step: Getting Lisinopril Covered by BCBS (Federated)

The path to covered lisinopril is short for most patients. These steps apply regardless of whether you are on a state BCBS affiliate or the FEP plan.

1. Confirm the formulary tier. Log into your BCBS member portal and search for "lisinopril" under the formulary/drug lookup tool. Note the tier, copay, and any listed restrictions.

2. Have your prescriber include the ICD-10 code. The most common coverage error is a missing or incorrect diagnosis code. For hypertension, that is I10. For CKD with hypertension, use the appropriate N18.x code alongside I12.x.

3. Request a 90-day supply. Most BCBS plans offer lower per-unit cost for maintenance medications dispensed as a 90-day mail-order fill. The FEP's mail pharmacy (CVS Caremark for FEP) charges roughly $10, $25 for a 90-day lisinopril supply [6].

4. Ask about generic substitution explicitly. If your prescriber wrote for brand Zestril or Prinivil, ask the pharmacy to substitute generic lisinopril. The FDA has confirmed bioequivalence for all approved generic formulations [25].

5. Keep labs current. A creatinine and potassium result from within the past 90 days in your chart reduces the chance of a plan-initiated safety review causing a dispensing delay.

6. Escalate promptly if denied. The 180-day internal appeal window starts from the denial date. Missing it forfeits your right to external review under ACA protections [11].

The ACC/AHA 2017 High Blood Pressure Guideline states: "Recommended medications for first-line antihypertensive treatment include thiazide diuretics, CCBs, and ACE inhibitors or ARBs" [3]. Lisinopril falls squarely within that first-line recommendation, giving your prescriber strong authoritative support when communicating with BCBS.

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) similarly noted: "Thiazide-type diuretics should be used in drug treatment for most patients with uncomplicated hypertension, either alone or combined with drugs from other classes," while acknowledging ACE inhibitors as preferred for patients with diabetes or CKD [26].

Lisinopril vs. Comparable Drugs: Formulary Position Comparison

Understanding where lisinopril sits relative to its therapeutic alternatives helps you anticipate what BCBS will require if lisinopril is contraindicated for you.

Losartan (ARB). Also a Tier 1 generic on most BCBS plans. BCBS rarely requires step therapy through lisinopril before approving losartan if the prescriber documents ACE inhibitor intolerance (cough or angioedema) [13]. The LIFE trial (N=9,193, Lancet 2002) showed losartan reduced the primary cardiovascular composite endpoint by 13% relative to atenolol in hypertensive patients with LVH [27].

Enalapril (ACE inhibitor). Comparable tier to lisinopril on most formularies. No clinical reason for BCBS to favor one over the other; substitution is pharmacist-discretionary in most states.

Ramipril (ACE inhibitor). Also generic, also Tier 1 on most BCBS plans. Ramipril 10 mg daily is the dose studied in the HOPE trial [18]. Some prescribers prefer it for high-cardiovascular-risk patients specifically because of that trial's data.

Brand-name ARBs (olmesartan, telmisartan). These are Tier 3 or Tier 4 on most BCBS formularies and will typically require a step-therapy demonstration that generic ACE inhibitors and losartan were tried first [12].

Frequently Asked Questions